SARS-CoV2 envelope protein: non-synonymous mutations and its consequences

Genomics. 2020 Nov;112(6):3890-3892. doi: 10.1016/j.ygeno.2020.07.001. Epub 2020 Jul 5.

Abstract

In the NCBI database, as on June 6, 2020, total number of available complete genome sequences of SARS-CoV2 across the world is 3617. The envelope (E) protein of SARS-CoV2 possesses several non-synonymous mutations over the transmembrane and C-terminus domains in 15 (0.414%) genomes among 3617 SARS-CoV2 genomes, analyzed. More precisely, 10(0.386%) out of 2588 genomes from the USA, 3(0.806%) from Asia, 1 (0.348%) from Europe and 1 (0.274%) from Oceania contained the missense mutations over the E-protein of SARS-CoV2 genomes. The C-terminus motif DLLV has been to DFLV and YLLV in the proteins from QJR88103 (Australia: Victoria) and QKI36831 (China: Guangzhou) respectively, which might affect the binding of this motif with the host protein PALS1.

Keywords: COVID-19; Envelope protein; Non-synonymous mutations; SARS-CoV2.

MeSH terms

  • COVID-19 / virology*
  • Coronavirus Envelope Proteins / chemistry
  • Coronavirus Envelope Proteins / genetics*
  • Coronavirus Envelope Proteins / metabolism*
  • Genome, Viral
  • Humans
  • Membrane Proteins / metabolism
  • Mutation*
  • Nucleoside-Phosphate Kinase / metabolism
  • SARS-CoV-2 / genetics*
  • SARS-CoV-2 / isolation & purification

Substances

  • Coronavirus Envelope Proteins
  • Membrane Proteins
  • envelope protein, SARS-CoV-2
  • Nucleoside-Phosphate Kinase
  • MPP5 protein, human